ACHIEVEMENT OF LDL-C GOALS IN PATIENTS AT MODERATE TO VERY HIGH CARDIOVASCULAR RISK ON LIPID-LOWERING DRUG THERAPY (CEPHEUS II)

被引：1
|
作者：
Logunova, Natalia [1 ]
Gurina, Natalia [1 ]
Boytsov, Sergey [2 ]
机构：
[1] AstraZeneca, Dept Med, Moscow, Russia
[2] Minist Hlth, State Res Ctr Prevent Med, Moscow, Russia
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.770
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO417
引用
收藏
页码：E236 / E237
页数：2
相关论文
共 50 条
  • [1] Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study
    Mostaza, J. M.
    Garcia-Ortiz, L.
    Tembra, M. A. Suarez
    Calle, P. Talavera
    Garcia, J. Chimeno
    Perez, V. Escolar
    Diaz-Diaz, J. L.
    Manzano-Espinosa, L.
    Catapano, A. L.
    Ray, K. K.
    Moya, G. Diaz
    Montoya, J. Pedro-Botet
    REVISTA CLINICA ESPANOLA, 2025, 225 (02): : 78 - 84
  • [2] ACHIEVEMENT OF LDL-C TARGETS IN CHINESE PATIENTS WITH VERY HIGH RISK ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RECEIVING INTENSIVE LIPID LOWERING THERAPY
    Cheng, Y.
    Dong, S.
    Shen, P.
    Sun, Y.
    Lin, H.
    Zhai, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [3] LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
    Catapano, A. L.
    Manu, M. C.
    Burden, A.
    Ray, K. K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2373 - 2373
  • [4] Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
    Lis, Anna
    Lis, Paulina
    Lowicka, Weronika
    Grabarczyk, Malgorzata
    Wita, Michal
    Zarczynski, Piotr
    Zarczynska, Malgorzata
    Haberka, Maciej
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [5] Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
    Wang, Xing
    He, Yan
    Wang, Tao
    Li, Chunming
    Ma, Zihui
    Zhang, Heng
    Ma, Handong
    Zhao, Hongxin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (04) : 307 - 315
  • [6] TREATMENT PATTERNS AND LDL-C CONTROL IN VERY HIGH-RISK PATIENTS RECEIVING LIPID-LOWERING THERAPY IN THE UNITED KINGDOM
    Beaini, Y.
    Danese, M.
    Sidelnikov, E.
    Villa, G.
    Catterick, D.
    Iqbal, M.
    Gleeson, M.
    Lubeck, D.
    Patel, J.
    VALUE IN HEALTH, 2020, 23 : S499 - S500
  • [7] Lipid-lowering therapy in patients with a 'normal' LDL-C Authors' response
    Nelson, Adam
    Nicholls, Stephen
    AUSTRALIAN PRESCRIBER, 2024, 47 (03) : 94 - 94
  • [8] Use of lipid-lowering agents and achievement of therapeutic goals in high cardiovascular risk patients in Argentina
    Sigal, Alan Rodrigo
    Antoniolli, Melisa
    Santi, Pilar Lopez
    Aquino, Nicolas
    Lerech, Ezequiel
    Botto, Fernando
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 (03): : 91 - 97
  • [9] Cardiovascular risk and lipid-lowering drug therapy
    Stulnig, T.
    DIABETOLOGE, 2012, 8 (07): : 568 - 572
  • [10] Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy
    Cesaro, Arturo
    Acerbo, Vincenzo
    Scialla, Francesco
    Golia, Enrica
    Concilio, Claudia
    Scherillo, Gianmaria
    De Michele, Gianantonio
    de Sio, Vincenzo
    Capolongo, Antonio
    Di Donato, Luisa
    Monaco, Maria Grazia
    Sperlongano, Simona
    Ruggiero, Alberto
    Gragnano, Felice
    Moscarella, Elisabetta
    Riccio, Carmine
    Calabro, Paolo
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2025, 32 (02) : 199 - 208
12345